Haque , Md. AminulTania, Umme2021-10-032021-10-0320212021-02ID: 16346032http://hdl.handle.net/10361/15111Cataloged from PDF version of thesis report.Includes bibliographical references (pages 38-48).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.Biosimilars is way more likely to genuine generic drugs of the innovator. Time to time expiry of generic drugs helps manufacturer to think about biosimilars which has wide cost effectiveness as well as expanded patient accessibility to medicines especially for malignancy patients. This article gives a refreshed audit of the biosimilar pharmaceutical products affirmed for disease treatment in the US and EU through strict pre-clinical, clinical as well as pharmacovigilance touchstones. Diverse oncological biosimilar drugs that are right now being utilized like epoetins (alpha and zeta), filgrastim, as well as mAb (rituximab, trastuzumab and bevacizumab) are being exhibited in this article.51 Pagesen-USBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.BiosimilarsInterchangeabilityCancer therapyMonoclonal antibodiesBiologic medicinesComparability exerciseThesis